Instruction for use: Epoetin alfa

Trade name of the drug – Aeprine, Binokrit, Repoetinum SP, Epocrin, Eprex, Erythropoetin alpha human recombinant

The Latin name of the substance Epoetin alfa

Epoetinum alfa (genus. Epoetini alfa)

Chemical name

Alpha- (1-165) -Erythropoietin (genetically engineered); A glycoprotein consisting of 165 amino acids

Gross formula

C815H1317N233O241S5

Pharmacological group:

Stimulators of hematopoiesis

The nosological classification (ICD-10)

C90 Multiple myeloma and malignant plasma cell neoplasms: Retikuloplasmocytosis; Rustitsky's disease; Rustitskogo-Kahler's disease; Plasma cell myeloma; Myelomatosis

C91 Lymphoid leukemia [lymphatic leukemia]: Lymphatic leukemia; Lymphoproliferative diseases; Neuroleukemia; Refractory acute lymphoblastic leukemia; Refractory lymphoblastic leukemia; Transformation of preleukemias; Chronic lymphocytic leukemia; Lymphoproliferative disorders

D63.0 Anemia in neoplasm: Anemia in chronic diseases; Anemia due to radiation damage; Radiation anemia; Anemia in patients with solid tumors; Pernicious anemia

D63.8 Anemia in other chronic diseases classified elsewhere: Anemia in chronic diseases; Anemia in immunological disorders; Anemia in peptic ulcer; Anemia in kidney diseases; Anemia with HIV treatment; Anemia in the background of chronic renal failure; Anemia in patients with myeloma; Symptomatic anemia; Symptomatic anemia of renal genesis; Anemia in HIV-infected patients; Renal anemia

CAS Code

113427-24-0

Pharmacology

Mode action - Antianemic, erythropoietic.

Stimulates mitosis and differentiation of erythroid progenitor cells. Increases the number of erythrocytes, reticulocytes, hemoglobin content, improves heart function and blood supply to tissues.

Bioavailability after SC administration is 25%, Cmax is reached after 12-18 hours; T1 / 2 up to 24 hours after SC administration; With iv injection T1 / 2 is 5-6 hours, with periodic injections in the blood does not cumulate.

Application of the substance Epoetin alfa

Anemia: with chronic renal failure, hemodialysis, HIV infection against zidovudine, cytostatic chemotherapy, in preterm infants; Preparation of patients with anemia for surgery with the expected massive blood loss.

Contraindications

Hypersensitivity, uncontrolled arterial hypertension, iron deficiency, pregnancy, breast-feeding.

Application of pregnancy and breastfeeding

The action category for fetus by FDA is C.

Side effects of the substance Epoetin alfa

Hypertension, headache, fatigue, asthenia, dizziness, arthralgia, retrosternal pain, nausea, vomiting, diarrhea, swelling, thrombophilia, seizures, skin reactions at the injection site.

Overdose

Symptoms: polycythemia and hematocrit change. Special treatment is required - temporarily cancel epoetin (before the normalization of hematocrit).

Routes of administration

SC or IV.

Precautions for the substance Epoetin alfa

Do not use in combination with solutions of other medicines. It is necessary to regularly monitor the hematocrit to prevent a decrease in effectiveness and development of resistance. It is recommended to use plastic syringes and containers, avoid glass.